Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 8/20 | 0.47 |
| ▸ | RXRA | P19793 | 8/20 | 0.47 |
| ▸ | RXRG | P48443 | 3/20 | 0.47 |
| ▸ | ICMT | O60725 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | PRKACG | P22612 | 1/20 | 0.36 |
| ▸ | PRKACB | P22694 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129444 | 1.00 | RXRB (0.47) | RXRBRXRARXRGICMTDHODH | |
| SCHEMBL30129509 | 0.85 | RXRA (0.47) | RXRBRXRARXRGICMTDHODH | |
| SCHEMBL23883577 | 0.85 | RXRA (0.47) | RXRBRXRARXRGICMTDHODH | |
| SCHEMBL23903772 | 0.79 | ICMT (0.46) | RXRBRXRARXRGICMTKIF11 | |
| SCHEMBL31210083 | 0.76 | RXRB (0.34) | RXRBRXRARXRGICMTDHODH | |
| SCHEMBL23883576 | 0.74 | LRRK2 (0.45) | KIF11SRCPRKACAPRKACGPRKACB | |
| SCHEMBL30129454 | 0.74 | LRRK2 (0.45) | KIF11SRCPRKACAPRKACGPRKACB | |
| SCHEMBL28910972 | 0.72 | POLB (0.39) | RXRBRXRARXRGRARGSMN1; SMN2 | |
| SCHEMBL23903848 | 0.71 | GPR84 (0.41) | RXRBRXRAICMTDHODHRARG | |
| SCHEMBL24601485 | 0.70 | RXRB (0.40) | RXRBRXRARXRGICMTCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319758-B2 | Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-06-03 | — | — | US | disclosed |
| EP-4126991-B9 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4126991-B1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4126991-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | Dow Global Technologies LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021202722-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021202722-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL(II) OR PALLADIUM(II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319758-B2 | Sterically hindered phosphino-urea supported nickel (II) or palladium (II) catalysts for the copolymerization of ethylene and polar comonomers | PCNA, NIT2, MCM7 | RXRB 4848/4885RXRA 4851/4885RXRG 4861/4885 |
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | PCNA, NIT2, MCM7 | RXRB 4848/4885RXRA 4851/4885RXRG 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.